Ignite Creation Date:
2024-05-05 @ 11:57 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00185393
Status:
COMPLETED
Last Update Posted:
2008-12-01
First Post:
2005-09-12
Brief Title:
Treatment With 90Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma Stage III or IV Having Achieved a Partial or Complete Remission After First Line Chemotherapy
Sponsor:
Bayer
Organization:
Bayer
Organization Data
Organization:
Bayer
Class:
INDUSTRY
Study ID:
90966
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Bayer
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
None
Responsible Party Affiliation:
None
Old Name:
Therapeutic Area Head
Old Organization:
Bayer Schering Pharma AG